My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
September 2009
Vol. 19 No. 9
Patient Care and Science
NIAID Funds Research on Shorter Antimicrobial Regimens

The National Institute of Allergy and Infectious Diseases (NIAID) recently funded two new clinical trials to help address the growing threat of antimicrobial resistance by investigating the effectiveness of shorter antimicrobial regimens.

Children’s Hospital of Philadelphia was awarded $1.5 million to study children with urinary tract infections to determine if treatment with antimicrobials can be shortened and still be effective. The hospital will enroll up to 1,000 children in the study. Duke University in Durham, N.C., received $1.4 million for a project testing the effectiveness of shorter antimicrobial regimens for hospitalized patients who acquire staphylococcal bloodstream infections following the use of intravenous catheters. Both institutions can qualify for additional funding if milestones are met during the six-year NIAID contracts. 

IDSA has been a strong advocate for funding this type of research. In 2007, in response to NIAID’s request for suggestions for studies that would help clarify the optimal antimicrobial therapy for common infectious diseases, IDSA submitted proposals for research focused on this issue. NIAID subsequently released a Broad Agency Announcement (BAA) in 2009 seeking proposals for targeted clinical trials to reduce antimicrobial resistance. The agency has continued this funding for 2010.

NIAID continues to solicit proposals for research to find improved treatment strategies that help minimize the development of antibiotic resistance, including research projects on acute ear infections in children, pneumonia, and bloodstream infections caused by gram-negative bacteria. For more information about NIAID opportunities, visit this page.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Top Stories
From the President: Protecting HCWs from Novel H1N1
IDSA Annual Meeting Reminders and Updates
IDSA Journal Club
Patient Care and Science
EIN: H1N1 and HCW Reassignment Questions
NIAID Funds Research on Shorter Antimicrobial Regimens
“Get Smart” Week Targets Inappropriate Antibiotic Use
Drug Approvals, Recalls, Adverse Events Update
Practice Management
Annual Meeting Features Helpful Practice Management Sessions
What ID Physicians Are Paid
Global ID
South African Clinic Successfully Integrates HIV/TB Care
New NIH Director Cites Global Health Among Top Priorities
Policy and Advocacy
IDSA Urges Changes in Adverse Event Reporting for Research
Help Us Oppose Elimination of Consultation Payments
IDSA Highlights Ways to Spur Development of New Antibiotics in FDA Meeting
HIVMA Urges Health Reformers to Remember People with HIV
HIVMA, IDSA Call for Repeal of Needle Exchange Federal Funding Ban
Your Colleagues
IDSA Recognized for Combating Antibiotic Resistance
Members on the Move
Welcome, New Members!
Education & Resources
Show Your Commitment to Influenza Vaccination
Vaccine Safety Fellowship Available

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.